Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic

Philippe Gorphe, Bruno Grandbastien, Andreas Dietz, Umamaheswar Duvvuri, Robert L. Ferris, Wojciech Golusinski, Floyd Christopher Holsinger, Sefik Hosal, George Lawson, Hisham Mehanna, Vinidh Paleri, Richard Shaw, Giovanni Succo, C. René Leemans and Christian Simon

INTRODUCTION

At the end of December 2019, Chinese public health authorities reported several cases of acute respiratory syndrome in Wuhan City, Hubei province in China (1). Since then, SARS-CoV-2, the cause of coronavirus disease 2019 (COVID-19), has spread across the globe, leading to the World Health Organization declaring a Public Health Emergency of international concern on 30th January 2020, declaring a pandemic (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200407-sitrep-78-covid-19.pdf?sfvrsn=bc43e1b_2). After a first wave between March and June in Europe followed by a gradual reduction of daily infections a second more significant wave emerged with daily case rates peaking in the beginning of November. Although rates reduced somewhat since, they remain high and well above the rates of the first wave. As of end of December 2020, more than 80 million people had been infected and more than 1.7 million patients died worldwide (https://covid19.who.int/?gclid=EAIaIQobChMI76X8g4fx7QIVGqd3Ch2uyA92EAYAYASAEgJkxvD_BwE).

Early on in the pandemic, data from Wuhan emerged suggesting an increased mortality among surgical patients during the incubation period of a COVID 19 pneumonia. While a requirement of ICU care in 44% of patients was noted, the mortality amounted to 20.5% (2). Also, data emerged on the potential risk of infection of health care workers related to head and neck interventions (3). These concerns together with a mounting experience of resource constraints were taken into consideration, when consensus guidelines for head and neck cancer treatment were developed based on expert opinion and Delphi exercises for both radiation therapy (RT) and surgery (4, 5). In these guidelines it was strongly agreed on by experts that operations should be delayed until
patients were negative on SARS-COV2 (repeat) tests. Also, for early-stage disease (i.e., T1, 2N0 oral cancers) a delay of up to 8 weeks with serial monitoring of the patient was found acceptable. To the contrary, for advanced-stage HNSCCs no delay was found to be acceptable. Early-stage oropharyngeal cancers were considered of lesser surgical priority and were ranking with that respect below advanced oral, laryngeal, and maxillary cancers, and also early-stage oral cancers. It was suggested that surgery for oropharyngeal cancer could be avoided as RT- and chemoradiation therapy (CRT) were considered to be alternative regimes that were comparably efficient in terms of cancer control with less risk for SARS-COV2 related mortality (4).

We therefore thought it was critical to analyze the pertinent literature to determine the safety and feasibility of surgery, both open and by transoral approaches for oropharyngeal cancers during the ongoing pandemic.

RISK FACTORS, INCREASED MORTALITY, AND SEVERITY OF A SARS-CoV-2 INFECTION

Twenty-two percent of patients hospitalized with laboratory confirmed COVID-19 are critically ill as shown in a prospective observational cohort study of 1,150 patients. Factors associated with in-hospital mortality were found to be advanced age (aHR 1.31), chronic cardiac disease (aHR 1.76), chronic pulmonary disease (aHR 2.94), and certain laboratory parameters i.e., d-dimers and interleukin 6 (6).

Genome wide association studies (GWAS) helped to identify certain genetic factors associated with severe COVID-19. Among them the 3p21.31 gene cluster as a genetic susceptibility locus and the AB0 blood group system emerged to be associated with a higher risk for severe COVID-19 with an OR 1.45 of group A vs. an OR 0.65 of group 0, thus being protective (7). The severity of the SARS-CoV-2 infection has been reported to be associated with the RT-qPCR cycle threshold, which correlates with the estimated viral load (8, 9).

One of the most important factors impacting on the severity of a SARS-CoV2 infection is the presence of cancer. In a retrospective study on 232 COVID-19 patients with various types of cancers and 519 without cancer that were matched statistically, patients with cancer had an OR 3.61 to develop a severe form of the disease (WHO guidelines) (10).

Surgery in SARS-COV2 positive patients is plagued with a 24% mortality rate. This mortality is associated with age, male gender, ASA-status, presence of a cancer, undertaking of an emergency procedure, and undertaking of a major procedure (11).

RISK FACTORS FOR HIGHER MORBIDITY OF A SARS-CoV-2-INFECTION IN CANCER PATIENTS

A more severe SARS-CoV2 infection in cancer patients is associated with age, ECOG-status, cancer stage, and the application of targeted/immunotherapy (10).

As an independent risk factor for death a positive smoking history emerged from a register of 200 patients with thoracic malignancies (12). Other factors associated with increased 30 days mortality in a cancer population with a SARS-CoV2 infection were found to be increased age, male gender, smoking status, number of comorbidities, ECOG performance status 2 or higher, active cancer, receipt of azithromycin plus hydroxychloroquine (13).

Looking at various treatment modalities for cancers and contributing risks a retrospective multi-center study on 205 cancer patients with laboratory-proven SARS-CoV2 infections revealed that receiving chemotherapy within 4 weeks before onset of symptoms was an independent risk factor for death during admission to the hospital (14).

However, within the UK Coronavirus Cancer Monitoring Project (UKCCMP) it was demonstrated that after adjusting for age, gender, and comorbidities, chemotherapy had NO effect on mortality, neither had immunotherapy, hormonal therapy, targeted therapy, or radiotherapy all within the past 4 weeks (15).

TREATMENT CONSIDERATIONS FOR OROPHARYNGEAL CANCER (OPC) DURING THE SARS-CoV-2 PANDEMIC

The treatment of OPCs should under normal circumstances not be delayed. A delay of 3 months would create a reduction of net survival by 16.8% in the age group between 50 and 59 and even 18.3% in the age group between 60 and 69 (16). Patients usually undergoing surgery for OPCs are often early-stage cancer patients and/or patients with early T-stages. Early stage HNSCC is particularly sensitive to a delay of treatment in terms of mortality risk as is OPC in comparison to oral cavity cancer (17).

Taken the risk of additional mortality from a SARS-CoV2 infection into account, older patients rather not benefit from an immediate treatment of their OPCs. In fact, in case of a nosocomial SARS-CoV2 infection rate of 5% patients above an age of 60 have an overall higher mortality, if immediately taken for a treatment vs. waiting for 2 months, until the infection rate reduces (16).

Typically, early-stage OPCs are surgically removed using transoral robotic surgery (TORS) or transoral laser microsurgery (TLM). Both are endoscopic surgical techniques. Alternative treatments for oropharyngeal cancers consist of radiotherapy with or without cisplatin. Treatment usually depends on patient and institutional factors. Radiation therapy and chemotherapy seem not to increase the risk of mortality of cancer patients with a SARS-CoV2 infection and thus are reasonable treatment options (15). Surgery however may confer a significant risk of 30-days mortality in the range of 24% in case of a SARS-CoV2-infection, if extended surgery is performed and done in an emergency setting (11). However, a prospective international cohort study comprising 1,137 patients treated with surgery for HNSCCs during the first wave SARS-CoV2 pandemic demonstrated a 30-day mortality of only 1, 2%. In this cohort the rate of SARS-CoV2 infections was only 3% suggesting that head and neck surgery can be undertaken safely during the pandemic as a consequence of
REFERENCES

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi:10.1016/S0140-6736(20)30111-7
2. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clin Med. (2020) 23:100331. doi:10.1016/j.eclinm.2020.100331
3. Mick P, Murphy R. Aerosol-generating otolaryngology procedures and the need for enhanced PPE during the COVID-19 pandemic: a literature review. J Otolaryngol Head Neck Surg. (2020) 49:29. doi:10.1186/s40493-020-00424-7
4. Mehanna H, Hardman JC, Shensen JA, Abou-Foul AK, Topf MC, Alfaarsi M, et al. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. Lancet Oncol. (2020) 21:e350–9. doi:10.1016/S1470-2045(20)30334-X
5. Thomson DJ, Palma D, Guckenberger M, Balenmpas P, Beiterl J, Blanchard P, et al. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys. (2020) 107:618–27. doi:10.1016/j.ijrob.2020.04.016
6. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. (2020) 395:1763–70. doi:10.1016/S0140-6736(20)31189-2
7. Ellingham D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med. (2020) 383:1522–34. doi:10.1056/NEJMoa2020283
8. Domeracki S, Clapp RN, Taylor K, Lu CM, Lampiris H, Blanc PD. Cycle threshold to test positivity in COVID-19 for return to work clearance in health care workers. J Occup Environ Med. (2020) 62:889–91. doi:10.1097/JOM.0000000000001996
9. Rao SN, Manisiero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. (2020) 9:573–86. doi:10.1007/s40121-020-00324-3
10. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. (2020) 21:893–903. doi:10.1016/S1470-2045(20)30309-0
11. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. (2020) 396:27–38. doi:10.1016/S0140-6736(20)31182-X
12. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. (2020) 21:914–22. doi:10.1016/S1470-2045(20)30314-4
13. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCCG19): a cohort study. Lancet. (2020) 395:1907–18. doi:10.1016/S0140-6736(20)31187-9
14. Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. (2020) 21:904–13. doi:10.1016/S1470-2045(20)30310-7
15. Lee LYW, Cazier JB, Starkey T, Turnbull CD, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other antcancer treatments: a prospective cohort study. Lancet. (2020) 395:1919–26. doi:10.1016/S0140-6736(20)31173-9
16. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. (2020) 21:1035–44. doi:10.1016/S1470-2045(20)30392-2
17. Murphy CT, Galloway TJ, Handorf EA, Egleston BL, Egleston BL, Wang LS, Mehra R, et al. Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States. J Clin Oncol. (2016) 34:169–78. doi:10.1200/JCO.2015.61.5906
18. Head and neck cancer surgery during the COVID-19 pandemic: an international, multicenter, observational cohort study. Cancer. (2020). doi:10.1002/cncr.3332019. [Epub ahead of print]
19. Aslam A, Singh J, Robilotti E, Chow K, Bist T, Reidy-Lagunes D, et al. SARS-CoV-2 surveillance and exposure in the perioperative setting with universal testing and Personal Protective Equipment (PPE) policies. Clin Infect Dis. (2020). doi:10.1093/cid/ciaa1607. [Epub ahead of print]
20. Glasby JC, Nepogodiev D, Simoes IFF, Omar O, Li E, Venn ML, et al. Elective surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study. J Clin Oncol. (2021) 39:66–78. doi:10.1200/JCO.20.01933

DISCUSSION

Surgery for oropharyngeal cancers during the pandemic seems feasible and safe. Delays should be in general avoided in particular for early-stage disease. An exception constitutes advanced age and high nosocomial SARS-CoV2 infection rates, which should prompt a delay of treatment. SARS-CoV2 screening prior surgery and sanitary precautions taken by hospitals seem sufficient to maintain an acceptably low complication rate and mortality. TORS may confer an advantage as being a technique with less droplet distribution than open surgical techniques.

AUTHOR CONTRIBUTIONS

PG, BG, CL, and CS designed the study and collected the data. PG, BG, CL, CS, HM, VP, and BS interpreted the data. CS supervised the project. All authors drafted the manuscript and contributed to the article and approved the submitted version.
21. Chow VLY, Chan JYW, Ho VWY, Lee GCC, Wong MMK, Wong STS, et al. Conservation of personal protective equipment for head and neck cancer surgery during COVID-19 pandemic. Head Neck. (2020) 42:1187–93. doi: 10.1002/hed.26215

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.